Fig. 2: Persistent NK cells were shifted toward an activated, less mature phenotype upon D-Rd treatment.

a Ratio of CD56^bright and CD56^dim cells relative to the total number of NK cells at baseline and upon treatment, normalized to the total number of T cells. b On-treatment to baseline ratio of positive cell fractions in D-Rd and Rd in function of the signal intensity centiles for a subset of markers across CD56^bright and CD56^dim NK cells. c Radviz projection with contour plots representing marker expression levels of CD56^bright and CD56^dim cells at baseline and upon D-Rd and Rd treatment. d Percentages of CD137⁺CD56^dim and CD56^bright NK cells relative to total CD56^dim and CD56^bright NK cells, respectively. e Percentages of subtypes of CD27 and CD69 NK cells relative to total NK cells. Br bright, D-Rd daratumumab plus lenalidomide and dexamethasone, NK natural killer, Rd lenalidomide and dexamethasone.